Solid Biosciences Touts Encouraging Results For Duchenne Gene Therapy, FDA Talks Planned

Solid Biosciences Inc. (NASDAQ:SLDB) shares are tumbling on Wednesday following a recent update regarding the company’s clinical trial for SGT-003, an investigational gene therapy.

Disease-Relevant Treatment Effect

The company on Wednesday reported interim data from its Phase 1/2 INSPIRE DUCHENNE clinical trial, where 40 participants have been dosed with SGT-003.

The new data included additional muscle biopsy, serum biomarker, cardiac function, and safety analyses.

The trial has shown promising results, including robust microdystrophin expression and improvements in muscle integrity, which are critical for patients suffering from Duchenne muscular dystrophy.

Additionally, SGT-003 has demonstrated an encouraging safety profile and has been well-tolerated among participants.

Regulatory Pathway

The company plans to meet with the FDA in the first half of 2026 to discuss a potential accelerated approval pathway for SGT-003, which could significantly impact its market position.

The company expects to provide an update in mid-2026.

In February, Solid Biosciences announced a regulatory update from its recent Type C meeting with the U.S. Food and Drug Administration (FDA) for SGT-003.

Solid Biosciences’ Technical Analysis

The stock is currently trading 18.9% above its 20-day simple moving average (SMA) and 31.6% above its 100-day SMA, indicating a strong short-term trend.

Over the past 12 months, shares have increased 33.87%, and they are currently positioned closer to their 52-week highs than lows.

The RSI is at 70.01, which is considered overbought territory, suggesting that the stock may be due for a correction. Meanwhile, the MACD is at 0.2936, above its signal line at 0.0927, indicating bullish momentum.

The combination of overbought RSI and bullish MACD suggests bearish momentum, indicating potential volatility ahead.

• Key Resistance: $8.50
• Key Support: $6.50

Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $14.12. Recent analyst moves include:

• Wedbush: Outperform (Maintains Target to $14.00) (Mar. 11)
• Needham: Buy (Maintains Target to $16.00) (Feb. 9)

Solid Biosciences Benzinga Edge Rankings

Below is the Benzinga Edge scorecard for Solid Biosciences, highlighting its strengths and weaknesses compared to the broader market:

• Momentum: Bullish (Score: 79.2) — Stock is outperforming the broader market.

The Verdict: Solid Biosciences’ Benzinga Edge signal reveals a strong momentum score, indicating positive market sentiment. However, the overbought RSI suggests caution for short-term traders as the stock may be due for a pullback.

SLDB Price Action: Solid Biosciences shares were down 9.72% at $7.38 at the time of publication on Wednesday, according to Benzinga Pro data.

Image via Shutterstock